Clinical Trial Finder

Inclusion Criteria:

• - Before conducting any study-specific procedures, voluntarily sign an informed consent form.

• - Be able and willing to participate throughout the entire study period and comply with study procedures.

• - participants ≥18 years of age.

• - Previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy (Refractory or intolerant to standard therapies, must have received the standard of care therapy) - Participants must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) - For participants who have received prior treatment with a checkpoint inhibitor there must be documented disease progression.

• - ECOG performance status of 0 or 1 before C1D1.

• - Part B Participants must be willing to provide fresh tumor biopsy (core biopsy) both pre-treatment and on-treatment, if clinically feasible.

• - Disease-free of active second/secondary or prior malignancies for ≥ 2 years Laboratory test results within the required parameters.

• - Women of childbearing potential (WOCBP) and men must agree to use adequate contraception.

Exclusion Criteria:

• - Participants with acute leukemia or CLL.

• - Participant with heart disease (NYHA ≥ Level II), myocardial infarction within the past 6 months, or unstable arrhythmia.

• - Fridericia-corrected QT interval (QTcF) > 470 msec, or the presence of congenital long QT syndrome, or a history of clinically significant electrocardiogram (ECG) abnormalities (including pericarditis) that, in the investigator's judgment, may affect the subject's safety.

• - Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy within 7 days before C1D1.

• - Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy.

• - Known human immunodeficiency virus (HIV) infection, known hepatitis B virus (HBV), or hepatitis C virus (HCV) infection, unless meeting the specific conditions.

• - History of major organ transplant and/or a bone marrow transplant.

• - Symptomatic central nervous system (CNS) malignancy or metastasis.

• - Serious nonmalignant disease.

• - Pregnant or nursing women.

• - Major surgery within 28 days prior to the first dose of study medication.

• - Prior anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) before the first dose of GV20-0251 on Cycle 1 Day 1 (C1D1), with the exceptions.

• - History of severe allergic reactions to biologic therapy, which in the investigator's judgment may increase the subject's risk.

• - Radiation therapy for symptomatic lesions within 14 days prior to C1D1 dosing.

• - Active substance abuse.

This is a Phase 1/2A non-randomized, open-label, multi-center study to be conducted in 2 parts (A and B). Part A is a safety run-in portion. A 3+3 dose escalation scheme will be used to evaluate the safety and tolerability of GV20-0251, and to establish the maximum tolerated dose (MTD) or the preliminary recommended Phase 2 dose (RP2D). In Part B, the Simon 2-stage design will be utilized to further characterize the anti-tumor activities, safety, tolerability, pharmacokinetics, and pharmacodynamics of GV20-0251 at the preliminary RP2D across multiple expansion cohorts involving eligible participants.

Arms

Interventions